DE69911206D1 - 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivate - Google Patents
2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivateInfo
- Publication number
- DE69911206D1 DE69911206D1 DE69911206T DE69911206T DE69911206D1 DE 69911206 D1 DE69911206 D1 DE 69911206D1 DE 69911206 T DE69911206 T DE 69911206T DE 69911206 T DE69911206 T DE 69911206T DE 69911206 D1 DE69911206 D1 DE 69911206D1
- Authority
- DE
- Germany
- Prior art keywords
- purin
- tetrahydro
- diol derivatives
- diol
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9813535.3A GB9813535D0 (en) | 1998-06-23 | 1998-06-23 | Chemical compounds |
PCT/EP1999/004270 WO1999067266A1 (en) | 1998-06-23 | 1999-06-23 | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69911206D1 true DE69911206D1 (de) | 2003-10-16 |
Family
ID=10834237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69911206T Expired - Lifetime DE69911206D1 (de) | 1998-06-23 | 1999-06-23 | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivate |
Country Status (8)
Country | Link |
---|---|
US (1) | US6534486B1 (de) |
EP (1) | EP1090021B1 (de) |
JP (1) | JP2002518513A (de) |
AT (1) | ATE249473T1 (de) |
AU (1) | AU4613899A (de) |
DE (1) | DE69911206D1 (de) |
GB (1) | GB9813535D0 (de) |
WO (1) | WO1999067266A1 (de) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6514949B1 (en) | 1994-07-11 | 2003-02-04 | University Of Virginia Patent Foundation | Method compositions for treating the inflammatory response |
YU44900A (sh) | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola |
BR9914526A (pt) * | 1998-10-16 | 2001-07-03 | Pfizer | Derivados de adenina |
US7378400B2 (en) | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
US7427606B2 (en) | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
US6232297B1 (en) | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
GB0022695D0 (en) | 2000-09-15 | 2000-11-01 | Pfizer Ltd | Purine Derivatives |
AU2002362443B2 (en) | 2001-10-01 | 2008-05-15 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof |
AU2002951247A0 (en) * | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
TWI346109B (en) * | 2004-04-30 | 2011-08-01 | Otsuka Pharma Co Ltd | 4-amino-5-cyanopyrimidine derivatives |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
CN103087133B (zh) * | 2004-05-26 | 2016-09-14 | 伊诺泰克制药公司 | 嘌呤衍生物作为腺苷a1受体激动剂及其用法 |
EP2266994B1 (de) | 2004-08-02 | 2013-04-03 | University Of Virginia Patent Foundation | 2-propynyl-adenosin-Analoga mit modifizierten 5'-Ribosegruppen mit A2A-Agonistenaktivität |
US7442687B2 (en) | 2004-08-02 | 2008-10-28 | The University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
WO2006028618A1 (en) | 2004-08-02 | 2006-03-16 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
MX2007003271A (es) * | 2004-09-20 | 2007-06-05 | Inotek Pharmaceuticals Corp | Derivados de purina y metodos de uso de los mismos. |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
GB0514809D0 (en) * | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
EP2532679B1 (de) | 2005-10-21 | 2017-04-12 | Novartis AG | Menschliche Antikörper gegen IL13 und therapeutische Verwendungen |
CA2627319A1 (en) * | 2005-11-30 | 2007-06-07 | Prakash Jagtap | Purine derivatives and methods of use thereof |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
GB0607950D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
US8258141B2 (en) | 2006-04-21 | 2012-09-04 | Novartis Ag | Organic compounds |
GB0607954D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
EP1889846A1 (de) | 2006-07-13 | 2008-02-20 | Novartis AG | Purinderivate als A2a Agonisten |
EP1903044A1 (de) | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosinderivate als Agonisten des A2A-Rezeptors |
ATE502943T1 (de) | 2006-09-29 | 2011-04-15 | Novartis Ag | Pyrazolopyrimidine als pi3k-lipidkinasehemmer |
KR20090075714A (ko) | 2006-10-30 | 2009-07-08 | 노파르티스 아게 | 소염제로서의 헤테로시클릭 화합물 |
FR2924430B1 (fr) * | 2007-11-30 | 2010-03-19 | Univ Bordeaux 2 | Procede de preparation de nanoparticules a base de molecules ou macromolecules amphiphiles fonctionnelles et leur utilisation |
WO2009087224A1 (en) | 2008-01-11 | 2009-07-16 | Novartis Ag | Pyrimidines as kinase inhibitors |
TW201031406A (en) | 2009-01-29 | 2010-09-01 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
MX2012001838A (es) | 2009-08-12 | 2012-02-29 | Novartis Ag | Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion. |
MY162604A (en) | 2009-08-17 | 2017-06-30 | Intellikine Llc | Heterocyclic compounds and uses thereof |
IN2012DN01453A (de) | 2009-08-20 | 2015-06-05 | Novartis Ag | |
LT2523669T (lt) | 2010-01-11 | 2017-04-25 | Inotek Pharmaceuticals Corporation | Akispūdžio mažinimo būdas, derinys ir rinkinys |
JP2013523739A (ja) | 2010-03-26 | 2013-06-17 | イノテック ファーマシューティカルズ コーポレイション | N6−シクロペンチルアデノシン(cpa)、cpa誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法 |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
EP2673277A1 (de) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4] triazolo [4, 3]pyridazinverbindungen als inhibitoren dec-met-tyrosinkinase |
US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
WO2012116217A1 (en) | 2011-02-25 | 2012-08-30 | Irm Llc | Compounds and compositions as trk inhibitors |
EP2755976B1 (de) | 2011-09-15 | 2018-07-18 | Novartis AG | 6-substituierte 3-(chinolin-6-ylthio)-[1,2,4-]triazolo-[4,3-a-]pyradine als tyrosinkinase |
EP2793893A4 (de) | 2011-11-23 | 2015-07-08 | Intellikine Llc | Verbesserte behandlungspläne unter verwendung von mtor-inhibitoren |
SI2807178T1 (sl) | 2012-01-26 | 2017-09-29 | Inotek Pharmaceuticals Corporation | Anhidridni polimorf (2R,3S,4R,5R)-5-(6-(ciklofentilamino)-9H-purin-9-il)-3,4-dihidroksite- trahidrofuran-2-il))metil nitrat in postopki njegove priprave |
CN104245701A (zh) | 2012-04-03 | 2014-12-24 | 诺华有限公司 | 有酪氨酸激酶抑制剂的组合产品和其应用 |
AU2014239222A1 (en) | 2013-03-15 | 2015-10-01 | Inotek Pharmaceuticals Corporation | Ophthalmic formulations |
WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Mdm2抑制劑與BRAF抑制劑之組合及其用途 |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
AU2015294889B2 (en) | 2014-07-31 | 2018-03-15 | Novartis Ag | Combination therapy |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2621470A1 (de) * | 1976-05-14 | 1977-12-01 | Pharma Waldhof Gmbh & Co | Nucleosidcarbonsaeurenitrile und ihre derivate, und verfahren zu ihrer herstellung |
GB9301000D0 (en) * | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
GB9414193D0 (en) * | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
AU3255097A (en) * | 1996-07-05 | 1998-02-02 | Novo Nordisk A/S | Novel (n)-alkoxyadenine derivatives acting as cytokine inhibitors |
-
1998
- 1998-06-23 GB GBGB9813535.3A patent/GB9813535D0/en not_active Ceased
-
1999
- 1999-06-23 WO PCT/EP1999/004270 patent/WO1999067266A1/en active IP Right Grant
- 1999-06-23 DE DE69911206T patent/DE69911206D1/de not_active Expired - Lifetime
- 1999-06-23 AT AT99929288T patent/ATE249473T1/de not_active IP Right Cessation
- 1999-06-23 US US09/720,193 patent/US6534486B1/en not_active Expired - Fee Related
- 1999-06-23 EP EP99929288A patent/EP1090021B1/de not_active Expired - Lifetime
- 1999-06-23 JP JP2000555917A patent/JP2002518513A/ja active Pending
- 1999-06-23 AU AU46138/99A patent/AU4613899A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2002518513A (ja) | 2002-06-25 |
AU4613899A (en) | 2000-01-10 |
EP1090021B1 (de) | 2003-09-10 |
ATE249473T1 (de) | 2003-09-15 |
WO1999067266A1 (en) | 1999-12-29 |
EP1090021A1 (de) | 2001-04-11 |
GB9813535D0 (en) | 1998-08-19 |
US6534486B1 (en) | 2003-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69911206D1 (de) | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivate | |
DE69903708T2 (de) | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivate | |
IS5779A (is) | 2-(púrín-9-ýl)-tetrahýdrófúran-3,4-díól afleiður | |
DK1056759T3 (da) | 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol-derivater | |
IS5774A (is) | 2-(púrín-9-ýl)-tetrahýdrófúran-3,4-díól afleiður | |
DK0948509T3 (da) | 2-(Purin-9-yl)-tetrahydrofuran-3,4-diolderivater | |
IT1309590B1 (it) | Derivati di 1-alcossi-polialchil-piperidine e loro impiego comeregolatori della polimerizzazione. | |
BR9901670A (pt) | Pó para aspersão térmica. | |
DK1137571T3 (da) | Kollisionsmodstandsdygtig dobbeltvægget konstruktion | |
FI892753A (fi) | Hoejdregleringsanordning foer armstoed pao stolar, saerskilt rullstolar. | |
BR0210879A (pt) | Método e sistema para prover métricas de performance armazenadas em uma disposição de pelo menos três dimensões, e, meio de armazenamento | |
MX9303709A (es) | Nucleosidos de purina substituidos e intermediarios de los mismos, que tienen actividad anti-viral y anti-cancerigena y composicion farmaceutica que los contiene. | |
DK630589D0 (da) | 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor-sammensaetning | |
DE68914750D1 (de) | Therapeutische Nucleoside. | |
BR0010882A (pt) | Agonistas receptores de adenosina a1 oralmente ativos e processo para uso de tal composição | |
SE9900972L (sv) | Konstruktion innefattande ett eller flera spant och en därvid medelst en förbindningsanordning fastgjord skiva samt användning därav | |
ZA99689B (en) | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives. | |
ZA991154B (en) | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives. | |
ITMI940356A0 (it) | Derivati della purina ad attivita' farmacologica loro uso e composizioni farmaceutiche che li contengono | |
SI1056759T1 (en) | 2-(purin-9-yl) -tetrahydrofuran-3, 4-diol derivatives | |
ES1039081Y (es) | Pieza ceramica perfeccionada para la construccion. | |
IT227969Y1 (it) | Armatura tubolare ad espansione per il presidio terapeutico della dissezione aortica, perfezionata. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8332 | No legal effect for de |